EU to review rare disease drugs market exclusivity

Biotech companies fear that tightening of the orphan drug legislation would remove the main incentive to produce drugs for rare diseases

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Related links

Related links

Related links in Nature Research

New products highlight ambiguity of orphan drug law

EMEA struggles with need to restructure

Related external links

EMEA

Eurordis

Alcimed

EBE

Rights and permissions

Reprints and Permissions

About this article

Further reading